Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 15, 2025, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 15, 2025, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg".